Creating new medications to reduce inflammation caused by arsenic exposure
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
This study is looking for new medicines that can help reduce inflammation caused by arsenic exposure, aiming to find safe and effective treatments for people who have been affected by it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Southern Research Institute NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10916421 on NIH RePORTER |
What this research studies
This research focuses on developing small molecule inhibitors that can effectively counteract the harmful inflammatory responses caused by arsenic compounds. The approach involves designing and synthesizing new compounds that target specific proteins involved in inflammation, such as BRD4 and RIPK3. These compounds will be tested for their ability to reduce inflammation in laboratory settings, with the goal of identifying safe and effective treatments for patients affected by arsenic exposure.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been exposed to arsenic and are experiencing severe inflammatory reactions.
Not a fit: Patients who have not been exposed to arsenic or do not exhibit inflammatory responses related to arsenic toxicity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, safer treatments for patients suffering from arsenic-induced skin injuries and inflammation.
How similar studies have performed: While the approach of developing inhibitors for inflammatory responses is promising, this specific combination of targets and compounds is relatively novel and has not been extensively tested in previous research.
Where this research is happening
Birmingham, United States
- Southern Research Institute — Birmingham, United States (Active)
Researchers
- Principal investigator: Augelli-Szafran, Corinne Elizabeth — Southern Research Institute
- Study coordinator: Augelli-Szafran, Corinne Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.